BOSTON, Aug. 10, 2018 /CNW/ -- Thornton Law Firm LLP is
investigating a potential lawsuit on behalf of purchasers of the
securities of Menlo Therapeutics Inc. (NASDAQ: MNLO) pursuant or
traceable to the registration statement and prospectus issued in
connection with Menlo's January 2018 initial public offering
("IPO"). The lawsuit seeks to recover damages for Menlo
investors/shareholders under the federal securities laws. MNLO
stock has dropped significantly after recent revelations that
Menlo's leading product, serlopitant, is no better than a placebo
at treating certain skin conditions.
If you purchased Menlo Therapeutic Inc. stock, you may have a
claim for damages resulting from misstatements in the Menlo
Therapeutics IPO prospectus and registration statement. To discuss
your legal rights, please contact Guillaume
O. Buell at the Thornton Law Firm at shareholder@tenlaw.com,
or call 617-720-1333.
The investigation involves Menlo's skin-treatment drug
"serlopitant" and whether Menlo has made false or misleading
statements regarding the drug's success in treating pruritis
associated with atopic dermatitis. In IPO materials provided to
investors, including Menlo's registration statement and prospectus,
Menlo may have made false and misleading statements regarding the
success of serlopitant in clinical trials, the measure by which
clinical data were measured, and whether serlopitant would advance
to Phase 3 clinical trials or obtain FDA approval. When Menlo came
clean to the market regarding the clinical failure of serlopitant,
its stock dropped nearly 70%, from approximately $38/share to as low as $7/share. Investors have lost millions of
dollars.
If you are a Menlo shareholder who suffered a loss, please
contact Guillaume O. Buell at the
Thornton Law Firm at shareholder@tenlaw.com, or call
617-720-1333.
Thornton Law Firm's securities attorneys specialize in
representing individual shareholders and institutional investors in
recovering damages caused by corporate fraud. Its attorneys have
decades of experience litigating securities fraud cases in courts
throughout the country and have a proven track record of recovering
losses on behalf of shareholders. This release may be considered
attorney advertising. Prior results do not guarantee any
outcome.
View original
content:http://www.prnewswire.com/news-releases/investigation-on-behalf-of-menlo-therapeutics-shareholders-for-recovery-of-investment-losses-300695605.html
SOURCE Thornton Law Firm, LLP